ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08945
0,00%
Bitcoin
66.936,47
-0,01%
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Eiger BioPharmaceuticals Inc (EIGR)

  7. Eiger BioPharmaceuticals Inc (EIGR) News

EIGR

Eiger BioPharmaceuticals (EIGR)

Eiger BioPharmaceuticals Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:EIGR
DatumZeitQuelleÜberschriftSymbolFirma
01/04/202417h12GlobeNewswire Inc.Eiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionNASDAQ:EIGREiger BioPharmaceuticals Inc
11/03/202421h03Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
24/01/202422h59Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
18/01/202423h49PR Newswire (US)Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanNASDAQ:EIGREiger BioPharmaceuticals Inc
08/01/202413h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
04/01/202414h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
04/01/202414h00PR Newswire (US)Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitNASDAQ:EIGREiger BioPharmaceuticals Inc
11/12/202322h01Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
04/12/202312h01Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
01/12/202322h02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:EIGREiger BioPharmaceuticals Inc
24/11/202312h01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
13/11/202322h01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
09/11/202322h27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
09/11/202322h14Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
09/11/202322h05PR Newswire (US)Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
03/11/202302h54Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
03/11/202302h14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
30/10/202321h51Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
20/10/202322h29Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:EIGREiger BioPharmaceuticals Inc
28/09/202322h54Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:EIGREiger BioPharmaceuticals Inc
12/09/202323h17Dow Jones NewsEiger BioPharmaceuticals to Discontinue Chronic Hepatitis Delta Study, Ends Licensing TalksNASDAQ:EIGREiger BioPharmaceuticals Inc
12/09/202322h42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
12/09/202322h05PR Newswire (US)Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis DeltaNASDAQ:EIGREiger BioPharmaceuticals Inc
06/09/202303h38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
06/09/202303h35Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:EIGREiger BioPharmaceuticals Inc
05/09/202322h05PR Newswire (US)Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:EIGREiger BioPharmaceuticals Inc
15/08/202312h00Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:EIGREiger BioPharmaceuticals Inc
14/08/202322h24Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:EIGREiger BioPharmaceuticals Inc
14/08/202322h09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:EIGREiger BioPharmaceuticals Inc
14/08/202322h05PR Newswire (US)Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:EIGREiger BioPharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:EIGR

Kürzlich von Ihnen besucht

HITB
FIROUSD
Firo
EU
IENAM
BNP ETF ENAM iNav
BIT
UR9KFT
UniCredit Bank
ASX
BKLKOC
BIT
P1ZFI0
NLBNPIT1ZFI0 20241220 800
USOTC
LIBLS
Landa App 3 (GM)
CSE
EVA
EVITRADE Health Systems Corp.
BIT
P20RN8
NLBNPIT20RN8 20991231 21...
USOTC
ARME
Armor Electric (CE)
TG
OLN
Olin
UPBT
GNOBTC
Gnosis
TIDE
BNBBTC
Binance Coin
LATK
CCOSETH
CrowdCoinage
COIN
GRAPUSD
GRAP
BIT
F19806
Vontobel Financial Produ...
BIT
P1TES5
NLBNPIT1TES5 20240621 25
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten